A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 4, 2012, Pages 386-392

  Thumbigere Math, Vivek ^a   Tu, Lam ^a   Huckabay, Sabrina ^a   Dudek, Arkadiusz Z ^a   Lunos, Scott ^b   Basi, David L ^a   Hughes, Pamela J ^a   Leach, Joseph W ^c   Swenson, Karen K ^c   Gopalakrishnan, Rajaram ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Academic Health Center   (United States)

^c PARK NICOLLET INSTITUTE   (United States)

Author keywords

bisphosphonate; breast cancer; diabetes; hypothyroidism; multiple myeloma; osteonecrosis; osteonecrosis of the jaw; pamidronate; zoledronate

Indexed keywords

PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL FEATURE; DIABETES MELLITUS; FEMALE; HUMAN; HYPOTHYROIDISM; JAW OSTEONECROSIS; KIDNEY CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; MULTICENTER STUDY; MULTIPLE MYELOMA; PROSTATE CANCER; RISK FACTOR; SMOKING; TREATMENT DURATION;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INCIDENCE; INJECTIONS, INTRAVENOUS; JAW DISEASES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; OSTEONECROSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84864374386     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182155fcb     Document Type: Article

References (45)

1. Fleisch H. Bisphosphonates: Mechanisms of action. Endocr Rev. 1998;19:80-100. (Pubitemid 29122075)
2. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res. 1973;11:269-280.
3. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: Pharmacology, mechanisms of action and clinical uses. Osteoporos Int. 1999;9(suppl 2):S66-S80. (Pubitemid 29231759)
4. Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int. 1991;49:407-415.
5. Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, et al. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1986;1:27-39. (Pubitemid 16018095)
6. Lowik CW, van der Pluijm G, van der Wee-Pals LJ, et al. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: The effect of a bisphosphonate. J Bone Miner Res. 1988;3:185-192.
7. Piper K, Boyde A, Jones SJ. The effect of 3-amino-1-hydroxypropylidene- 1,1-bisphosphonate (ADP) on the resorptive function of osteoclasts of known nuclear number. Calcif Tissue Int. 1994;54:56-61. (Pubitemid 24010518)
8. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10:1478-1487.
9. Reszka AA, Halasy-Nagy JM, Masarachia PJ, et al. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis: A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem. 1999;274:34967-34973. (Pubitemid 129509546)
10. Diel IJ, Solomayer EF, Bastert G. Bisphosphonates and the prevention of metastasis: First evidences from preclinical and clinical studies. Cancer. 2000;88:3080-3088. (Pubitemid 30413194)
11. Senaratne SG, Pirianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000;82:1459-1468. (Pubitemid 30175914)
12. Tassone P, Forciniti S, Galea E, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia. 2000;14:841-844. (Pubitemid 30235061)
13. Pietschmann P, Stohlawetz P, Brosch S, et al. The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells. Calcif Tissue Int. 1998;63:325-330. (Pubitemid 28443417)
14. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002;62:6538-6544. (Pubitemid 35364119)
15. Ledoux D, Hamma-Kourbali Y, Di Benedetto M, et al. A new dimethyl ester bisphosphonate inhibits angiogenesis and growth of human epidermoid carcinoma xenograft in nude mice. Anticancer Drugs. 2006;17:479-485. (Pubitemid 44309992)
16. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer. 1997;80:1652-1660. (Pubitemid 27444037)
17. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-1541. (Pubitemid 26411651)
18. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma: Myeloma Aredia Study Group. N Engl J Med. 1996;334:488-493. (Pubitemid 26067736)
19. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333: 1437-1443.
20. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042-4057. (Pubitemid 46606220)
21. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20: 3719-3736. (Pubitemid 34983232)
22. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-534. (Pubitemid 38542516)
23. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-1575. (Pubitemid 41525412)
24. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 2005;23:8580-8587. (Pubitemid 46211499)
25. Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: The risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol. 2007;4:42-55. (Pubitemid 46017693)
26. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008; 23:826-836. (Pubitemid 351768801)
27. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-761. (Pubitemid 46780635)
28. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-376.
29. Thumbigere-Math V, Sabino MC, Gopalakrishnan R, et al. Bisphosphonate-related osteonecrosis of the jaw: Clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg. 2009;67:1904-1913.
30. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol. 2006;24:945-952. (Pubitemid 46638849)
31. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006; 91:968-971. (Pubitemid 44023154)
32. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27:5356-5362.
33. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99-102; discussion 99-102.
34. Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology (Williston Park). 2006;20:1053-1062; discussion 1065-1066. (Pubitemid 46940833)
35. Tosi P, Zamagni E, Cangini D, et al. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood. 2006;108:3951-3952. (Pubitemid 44864588)
36. Pozzi S, Marcheselli R, Sacchi S, et al. Bisphosphonate-associated osteonecrosis of the jaw: A review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma. 2007;48:56-64. (Pubitemid 46978624)
37. Dimopoulos MA, Kastritis E, Moulopoulos LA, et al. The incidence of osteonecrosis of the jaw (ONJ) in patients with multiple myeloma who receive biphosphonates depends on the type of biphosphonate. (American Society of Hematology Annual Meeting Abstracts). 2005;106:637.
38. Mavrokokki T, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415-423. (Pubitemid 46343586)
39. Khamaisi M, Regev E, Yarom N, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab. 2007;92:1172-1175. (Pubitemid 46465699)
40. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A casecontrol study. J Oral Maxillofac Surg. 2008;66:625-631. (Pubitemid 351381804)
41. Ahmed LA, Schirmer H, Berntsen GK, et al. Self-reported diseases and the risk of non-vertebral fractures: The Tromso study. Osteoporos Int. 2006;17:46-53. (Pubitemid 41798027)
42. Vestergaard P, Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: A nationwide follow-up study in 16,249 patients. Thyroid. 2002;12:411-419. (Pubitemid 34602601)
43. Vestergaard P, Rejnmark L, Mosekilde L. Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int. 2005; 77:139-144. (Pubitemid 41569743)
44. Feitosa Dda S, Bezerra Bde B, Ambrosano GM, et al. Thyroid hormones may influence cortical bone healing around titanium implants: A histometric study in rats. J Periodontol. 2008;79:881-887.
45. Natori J, Shimizu K, Nagahama M, et al. The influence of hypothyroidism on wound healing: An experimental study. Nippon Ika Daigaku Zasshi. 1999;66:176-180.